Imidazopyridyl compounds as aldosterone synthase inhibitors

  • Bioorg Med Chem Lett. 2017 Jan 15;27(2):143-146. doi: 10.1016/j.bmcl.2016.12.003.
Brent R Whitehead  1 ,  Michael M-C Lo  2 ,  Amjad Ali  2 ,  Min K Park  2 ,  Scott B Hoyt  2 ,  Yusheng Xiong  2 ,  Jiaqiang Cai  3 ,  Emma Carswell  3 ,  Andrew Cooke  3 ,  John MacLean  3 ,  Paul Ratcliffe  3 ,  John Robinson  3 ,  D Jonathan Bennett  3 ,  Joseph A Clemas  2 ,  Tom Wisniewski  2 ,  Mary Struthers  2 ,  Doris Cully  2 ,  Douglas J MacNeil  2
Affiliations
  • 1. MRL, Rahway, NJ 07065, USA. Electronic address: [email protected].
  • 2. MRL, Rahway, NJ 07065, USA.
  • 3. MRL, Newhouse, Lanarkshire ML1 5SH, United Kingdom.
PMID: 27979595 DOI: 10.1016/j.bmcl.2016.12.003
Abstract

The inhibition of aldosterone synthase (CYP11B2) may be an effective treatment of hypertension and heart failure, among Other ailments. Previously reported benzimidazole CYP11B2 inhibitors led the way for bioisosteric imidazopyridines that are both potent and selective over CYP11B1.

Keywords
Aldosterone; CYP11B2; Heart failure; Hypertension; Imidazopyridine.